Subsequent Events	3 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events On April 1, 2026, the Company issued 43,885 shares of common stock to eligible employees pursuant to the NeurAxis, Inc. 2025 Employee Stock Purchase Plan effective as of July 1, 2025 and subject to shareholder approval by July 1, 2026. On April 9, 2026, the Company’s Board of Directors approved the cancelation of 1,319,394 stock options issued under the 2017 Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and the grant of an equivalent amount of RSUs with immediate vesting under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, subject to shareholder approval. The stock option cancelation and RSU grant will be treated as a modification under ASC 718, Compensation—Stock Compensation, whereby the Company will recognize incremental compensation cost as the excess of the fair value of the granted RSUs over the fair value of the stock options immediately before the exchange. The Company estimates $4,250,000 of incremental compensation cost will be recorded upon approval of the exchange by the shareholders. On April 10, 2026, the Company’s Board of Directors declared a dividend on the Series B Preferred Stock. Holders of record of the Company’s Series B Preferred Stock as the record date of April 21, 2026, received a stock dividend on April 28, 2026, of the Company’s par value $0.001 Common Stock for every share of Series B Preferred Stock. The Company issued 510,605 shares of Common Stock based on the 8.5% per annum cumulative dividend rate. On April 22, 2026, the Company granted 40,000 RSUs to an employee and issued 27,483 shares of common stock, net of taxes, upon vesting. On May 7, 2026, the Company issued 72,282 shares of common stock to an investor upon conversion of an equivalent amount of Series B Preferred Stock. In April and May of 2026, pursuant to the August 2025 At The Market Offering Agreement with Craig-Hallum Capital Group LLC, the Company issued 242,255 shares of common stock to investors for gross proceeds of $1,982,528 with such shares registered pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-283798), previously filed with the Securities and Exchange Commission (“SEC”) on December 13, 2024, and declared effective on February 11, 2025, and the related prospectus supplements filed with the SEC on August 29, 2025, October 23, 2025, and April 21, 2026. In April and May of 2026, the Company issued 37,850 shares of common stock upon exercise of an equivalent amount of common stock warrants for gross proceeds of $90,083. The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no other events that have occurred that would require adjustments to our disclosures in the condensed financial statements.

Subsequent Events

3 Months Ended

Mar. 31, 2026

16. Subsequent Events

On April 1, 2026, the Company issued 43,885 shares of common stock to eligible employees pursuant to the NeurAxis, Inc. 2025 Employee Stock Purchase Plan effective as of July 1, 2025 and subject to shareholder approval by July 1, 2026.

On April 9, 2026, the Company’s Board of Directors approved the cancelation of 1,319,394 stock options issued under the 2017 Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and the grant of an equivalent amount of RSUs with immediate vesting under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, subject to shareholder approval. The stock option cancelation and RSU grant will be treated as a modification under ASC 718, Compensation—Stock Compensation, whereby the Company will recognize incremental compensation cost as the excess of the fair value of the granted RSUs over the fair value of the stock options immediately before the exchange. The Company estimates $4,250,000 of incremental compensation cost will be recorded upon approval of the exchange by the shareholders.

On April 10, 2026, the Company’s Board of Directors declared a dividend on the Series B Preferred Stock. Holders of record of the Company’s Series B Preferred Stock as the record date of April 21, 2026, received a stock dividend on April 28, 2026, of the Company’s par value $0.001 Common Stock for every share of Series B Preferred Stock. The Company issued 510,605 shares of Common Stock based on the 8.5% per annum cumulative dividend rate.

On April 22, 2026, the Company granted 40,000 RSUs to an employee and issued 27,483 shares of common stock, net of taxes, upon vesting.

On May 7, 2026, the Company issued 72,282 shares of common stock to an investor upon conversion of an equivalent amount of Series B Preferred Stock.

In April and May of 2026, pursuant to the August 2025 At The Market Offering Agreement with Craig-Hallum Capital Group LLC, the Company issued 242,255 shares of common stock to investors for gross proceeds of $1,982,528 with such shares registered pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-283798), previously filed with the Securities and Exchange Commission (“SEC”) on December 13, 2024, and declared effective on February 11, 2025, and the related prospectus supplements filed with the SEC on August 29, 2025, October 23, 2025, and April 21, 2026.

In April and May of 2026, the Company issued 37,850 shares of common stock upon exercise of an equivalent amount of common stock warrants for gross proceeds of $90,083.

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no other events that have occurred that would require adjustments to our disclosures in the condensed financial statements.